Studies on Some Haemostatic Parameters in Patients with Myasthenia Gravis Attending Imo State Teaching Hospital, Orlu, Nigeria
DOI:
https://doi.org/10.37506/ep5y1726Keywords:
Myasthenia gravis, haemostasis, fibrinogen, prothrombin time, APTT, autoimmune disorders.Abstract
Background: Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating
muscle weakness and fatigue, which can lead to severe complications such as myasthenic crisis. This study aimed to
evaluate specific haemostatic parameters in MG patients attending the Neurology Clinic at Imo State Teaching Hospital,
Orlu, Nigeria.
Methods: A cross-sectional comparative study was conducted involving 50 participants: 25 diagnosed MG patients
and 25 age- and gender-matched healthy controls. After obtaining informed consent, fasting blood samples were
collected and analyzed for prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen
levels using the Sysmex CA-50 coagulation analyzer. Data were analyzed using SPSS version 27, with significance set
at p<0.05.
Results: MG patients showed significantly higher mean values of PT (15.30±1.95 s), APTT (35.60±3.74 s), and fibrinogen
(442.52±95.45 mg/dL) compared to controls (p<0.0001). No significant differences in these parameters were found
when stratified by gender or age.
Conclusion: The study demonstrates that MG is associated with elevated haemostatic markers such as fibrinogen, PT,
and APTT, indicating possible subclinical coagulation disturbances. Age and gender had no significant effect on these
parameters in MG patients. Further research on inflammatory markers may improve management and prognosis in MG.
Downloads
References
Punga AR, et al. Lancet Neurol. 2022;21(5):478-490.
Huijbers MG, et al. J Autoimmun. 2022; 128:102814.
Aricha R, et al. Front Immunol. 2021; 12:657307.
Uzawa A, et al. J Neuroimmunol. 2021; 360:577703.
Giannoccaro MP, et al. Neurol Sci. 2022;43(4):
–2033.
Gilhus NE. Lancet Neurol. 2019;18(4):318-330.
Burns TM, et al. Neurology. 2018;90(10):e755–e761.
Gelinas D, et al. Muscle Nerve. 2022;65(1):50-58.
Poëa-Guyon S, et al. Brain. 2020;143(6):1716–1728.
Gajdos P, et al. Neuromuscul Disord. 2022;32(3):
–259.
Kumar V, Abbas A, Aster JC. Robbins and Cotran
Pathologic Basis of Disease. 10th ed. Elsevier; 2021.
Kratz A, Ferraro M, Sluss PM. Am J Clin Pathol. 2004;
:241–250.
Gilhus NE. Nat Rev Neurol. 2019;15(5):269-282.
Poëa-Guyon S, et al. Ann Neurol. 2020;87(6):937–951.
Aricha R, et al. Autoimmun Rev. 2021;20(8):102815.
Uzawa A, et al. Neurobiol Dis. 2021;153:105318.
Burns TM, et al. Neuromuscul Disord. 2018;28(9):
–765.
Gelinas D, et al. Muscle Nerve. 2022;66(1):12–20.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
